Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2024 2
2025 7
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
ctDNA monitoring using tumor-informed copy number analysis.
Zhou Z, Cutts R, Hrebien S, Zhang CX, Garcia-Murillas I, Zhang WZ, Frankell AM, Cooper WN, Roshan A, Turner NC, Kaplan T, Rosenfeld N, Zhao H. Zhou Z, et al. EMBO Mol Med. 2026 Mar 19. doi: 10.1038/s44321-026-00399-4. Online ahead of print. EMBO Mol Med. 2026. PMID: 41857451 Free article.
Methods to detect circulating tumor DNA (ctDNA) enable minimally invasive responsive monitoring of cancer dynamics. However, sensitive and cost-effective methods are still lacking. Current methods for detecting cancer signals in shallow whole-genome sequencing (sWGS …
Methods to detect circulating tumor DNA (ctDNA) enable minimally invasive responsive monitoring of cancer dynamics. However, sensitiv …
Loss of CTLH component MAEA impairs DNA repair and replication and leads to developmental delay.
Hough SH, Jhujh SS, Awwad SW, Lewis OE, Lam S, Thomas JC, Mosler T, Bader A, Bartik L, McKee S, Amudhavalli S, Colin E, Damseh N, Clement E, Cacheiro P, Majumdar A, Smedley D, Fluss J, Giannini R, Thiffault I, Zagnoli Vieira G, Belotserkovskaya R, Smerdon SJ, Beli P, Galanty Y, Carnie CJ, Stewart GS, Jackson SP. Hough SH, et al. EMBO Mol Med. 2026 Feb;18(2):492-513. doi: 10.1038/s44321-025-00352-x. Epub 2025 Dec 19. EMBO Mol Med. 2026. PMID: 41420108 Free PMC article.
FOXO1 links KRAS G12D and G12V alleles to glutamine and nitrogen metabolism in colorectal cancer.
Ber S, Yang M, Sciacovelli M, Samarajiwa S, Patel K, Nikitopoulou E, Howitt A, Cook SJ, Venkitaraman AR, Frezza C, Esposito A. Ber S, et al. EMBO Rep. 2026 Jan;27(1):142-162. doi: 10.1038/s44319-025-00641-z. Epub 2025 Nov 20. EMBO Rep. 2026. PMID: 41266617 Free PMC article.
These results highlight a previously unreported mutant-specific effect of KRAS alleles on metabolism and signalling that could be potentially harnessed for cancer therapy....
These results highlight a previously unreported mutant-specific effect of KRAS alleles on metabolism and signalling that could be potentiall …
A Polygenic Risk Score for Late Bladder Toxicity Following Radiotherapy for Non-Metastatic Prostate Cancer.
Farazi M, Yang X, Gehl CJ, Barnett GC, Burnet NG, Chang-Claude J, Parker CC, Dunning AM, Azria D, Choudhury A, Rancati T, De Ruysscher D, Seibold P, Sperk E, Talbot CJ, Veldeman L, Webb AJ, Elliott R, Aguado-Barrera ME, Carballo AM, Fuentes-Ríos O, Gómez-Caamaño A, Peleteiro P, Vega A, Ostrer H, Rosenstein BS, Saito S, Parliament M, Usmani N, Marples B, Chen Y, Morrow G, Messing E, Janelsins MC, Hall W, West CML, Auer PL, Kerns SL. Farazi M, et al. Cancer Epidemiol Biomarkers Prev. 2025 May 2;34(5):795-804. doi: 10.1158/1055-9965.EPI-24-1228. Cancer Epidemiol Biomarkers Prev. 2025. PMID: 40029246 Free PMC article.
BACKGROUND: Late bladder toxicity is a concern for patients receiving prostate cancer radiotherapy and negatively affects survivors. Few risk factors are known beyond the radiation dose and volume of bladder exposed. ...IMPACT: PRS-guided treatment planning in radiation on …
BACKGROUND: Late bladder toxicity is a concern for patients receiving prostate cancer radiotherapy and negatively affects survivors. …
Haploinsufficient phenotypes promote selection of PTEN and ARID1A-deficient clones in human colon.
Skoufou-Papoutsaki N, Adler S, Mehmed S, Tume C, Olpe C, Morrissey E, Kemp R, Girard AC, Moutin EB, Chilamakuri CSR, Miller JL, Lindskog C, Werle F, Marks K, Perrone F, Zilbauer M, Tourigny DS, Winton DJ. Skoufou-Papoutsaki N, et al. EMBO Rep. 2025 Mar;26(5):1269-1289. doi: 10.1038/s44319-025-00373-0. Epub 2025 Feb 7. EMBO Rep. 2025. PMID: 39920335 Free PMC article.
Cancer driver mutations are defined by their high prevalence in cancers and presumed rarity in normal tissues. However, recent studies show that positive selection in normal epithelia can increase the prevalence of some cancer drivers. To determine their true can …
Cancer driver mutations are defined by their high prevalence in cancers and presumed rarity in normal tissues. However, recent studie …
Modeling Drug Responses and Evolutionary Dynamics Using Patient-Derived Xenografts Reveals Precision Medicine Strategies for Triple-Negative Breast Cancer.
Shea A, Eyal-Lubling Y, Guerrero-Romero D, Manzano Garcia R, Greenwood W, O'Reilly M, Georgopoulou D, Callari M, Lerda G, Wix S, Giovannetti A, Masina R, Esmaeilishirazifard E, Cope W, Martin AG, Nagano A, Young L, Kupczak S, Cheng Y, Bardwell H, Provenzano E, Kane J, Lay J, Grybowicz L, McAdam K, Caldas C, Abraham J, Rueda OM, Bruna A. Shea A, et al. Cancer Res. 2025 Feb 1;85(3):567-584. doi: 10.1158/0008-5472.CAN-24-1703. Cancer Res. 2025. PMID: 39514406 Free PMC article.
However, high intermodel variability and permanent nongenomic transcriptional changes constrain their use for personalized cancer therapy. This work highlights important considerations associated with preclinical drug response modeling and potential uses of the platform to …
However, high intermodel variability and permanent nongenomic transcriptional changes constrain their use for personalized cancer the …
FOXR2 Targets LHX6+/DLX+ Neural Lineages to Drive Central Nervous System Neuroblastoma.
Jessa S, De Cola A, Chandarana B, McNicholas M, Hébert S, Ptack A, Faury D, Tsai JW, Korshunov A, Phoenix TN, Ellezam B, Jones DTW, Taylor MD, Bandopadhayay P, Pathania M, Jabado N, Kleinman CL. Jessa S, et al. Cancer Res. 2025 Jan 15;85(2):231-250. doi: 10.1158/0008-5472.CAN-24-2248. Cancer Res. 2025. PMID: 39495206 Free PMC article.
Scribble Deficiency Promotes Pancreatic Ductal Adenocarcinoma Development and Metastasis.
Bermejo-Rodriguez C, Araos Henríquez J, Caligiuri G, Pinto Teles S, Park Y, Evans A, Barrera LN, Neesse A, Grützmann R, Aust D, Rümmele P, Knösel T, Narita M, Narita M, Campbell F, Öhlund D, Pilarsky C, Dow LE, Humbert PO, Biffi G, Tuveson DA, Perez-Mancera PA. Bermejo-Rodriguez C, et al. Cancer Res. 2024 Sep 16;84(18):2968-2984. doi: 10.1158/0008-5472.CAN-23-3419. Cancer Res. 2024. PMID: 39037766 Free PMC article.
These results indicate that SCRIB deficiency enhances cancer cell survival and remodels the tumor microenvironment to accelerate PDAC development and progression, establishing the tumor suppressor function of SCRIB in advanced pancreatic cancer. Significance: SCRIB …
These results indicate that SCRIB deficiency enhances cancer cell survival and remodels the tumor microenvironment to accelerate PDAC …
Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma.
Corcoran SR, Phelan JD, Choi J, Shevchenko G, Fenner RE, Yu X, Scheich S, Hsiao T, Morris VM, Papachristou EK, Kishore K, D'Santos CS, Ji Y, Pittaluga S, Wright GW, Urlaub H, Pan KT, Oellerich T, Muppidi J, Hodson DJ, Staudt LM. Corcoran SR, et al. Cancer Discov. 2024 Sep 4;14(9):1653-1674. doi: 10.1158/2159-8290.CD-23-0802. Cancer Discov. 2024. PMID: 38683128